Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.

Meczes EL, Azim-Araghi A, Ottley CJ, Pearson DG, Tilby MJ.

Biochem Pharmacol. 2005 Dec 5;70(12):1717-25. Epub 2005 Nov 2.

PMID:
16259963
2.

Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

Harrington CF, Le Pla RC, Jones GD, Thomas AL, Farmer PB.

Chem Res Toxicol. 2010 Aug 16;23(8):1313-21. doi: 10.1021/tx100023c.

PMID:
20666396
3.

Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.

Reed E, Gupta-Burt S, Litterst CL, Poirier MC.

Carcinogenesis. 1990 Dec;11(12):2117-21.

PMID:
1979937
4.

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Tilby MJ, Johnson C, Knox RJ, Cordell J, Roberts JJ, Dean CJ.

Cancer Res. 1991 Jan 1;51(1):123-9.

5.

Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.

Welters MJ, Maliepaard M, Jacobs-Bergmans AJ, Baan RA, Schellens JH, Ma J, van der Vijgh WJ, Braakhuis BJ, Fichtinger-Schepman AM.

Carcinogenesis. 1997 Sep;18(9):1767-74.

PMID:
9328174
6.
7.

The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.

Plooy AC, Fichtinger-Schepman AM, Schutte HH, van Dijk M, Lohman PH.

Carcinogenesis. 1985 Apr;6(4):561-6.

PMID:
4039227
8.

Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.

Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, Fichtinger-Schepman AM.

Biochemistry. 1995 Jul 4;34(26):8474-80.

PMID:
7599137
9.

Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis.

Vrána O, Kiseleva VI, Poverenny AM, Brabec V.

Eur J Pharmacol. 1992 May 12;226(1):5-13.

PMID:
1397055
10.

Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.

Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.

Clin Cancer Res. 1996 Nov;2(11):1829-35.

11.

Characterization of monoclonal antibodies against (1R,2R)-cyclohexanediamine platinum(II)-DNA adduct.

Hirose J, Inoue K, Morimoto E, Iwamoto H, Yamaguti Y, Kitase M, Inagaki K, Hiromi K.

Biol Pharm Bull. 1996 Sep;19(9):1220-2.

PMID:
8889045
12.
13.

Kinetics of reaction of cis-diamminedichloroplatinum(II) with DNA.

Försti A, Leppälä S, Takala M, Laatikainen R, Hemminki K.

Pharmacol Toxicol. 1989 Jan;64(1):120-5.

PMID:
2755902
14.

Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?

Fichtinger-Schepman AM, van Dijk-Knijnenburg HC, van der Velde-Visser SD, Berends F, Baan RA.

Carcinogenesis. 1995 Oct;16(10):2447-53.

PMID:
7586150
15.

Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels.

Fichtinger-Schepman AM, Baan RA, Berends F.

Carcinogenesis. 1989 Dec;10(12):2367-9.

PMID:
2591026
16.

Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.

Fichtinger-Schepman AM, Dijt FJ, Bedford P, van Oosterom AT, Hill BT, Berends F.

IARC Sci Publ. 1988;(89):321-8.

PMID:
3198216
17.

Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D, Yuspa SH.

Proc Natl Acad Sci U S A. 1982 Nov;79(21):6443-7.

18.

Postlabeling detection of DNA adducts of antitumor alkylating agents.

Zhou GH, Teicher BA, Frei E 3rd.

Cancer Chemother Pharmacol. 1996;38(1):71-80.

PMID:
8603455
19.

DNA adducts of cisplatin and carboplatin in tissues of cancer patients.

Poirier MC, Egorin MJ, Fichtinger-Schepman AM, Yuspa SH, Reed E.

IARC Sci Publ. 1988;(89):313-20.

PMID:
3058599
20.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Liedert B, Pluim D, Schellens J, Thomale J.

Nucleic Acids Res. 2006 Mar 29;34(6):e47.

Supplemental Content

Support Center